Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • HDAC
    (3)
  • Apoptosis
    (1)
  • Autophagy
    (1)
  • ROCK
    (1)
  • Others
    (8)
Filter
Search Result
Results for "

hdac1/2 in 3

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    11
    TargetMol | Inhibitors_Agonists
HDAC1/2-IN-3
HDAC1 2-IN-3
T395672121516-17-2
HDAC1/2-IN-3 is an inhibitor of both HDAC1 and HDAC2, demonstrating IC50 values of 0-5 nM and 5-10 nM, respectively.
  • Inquiry Price
Size
QTY
BRD4097
T305791550053-19-4In house
BRD4097, a negative control in the HDAC1 2 3 8 assay, is a selective histone deacetylase (HDAC3) inhibitor that can be used to protect b-cells and improve insulin resistance, help promote cognitive function and enhance learning and memory formation.
  • Inquiry Price
6-8weeks
Size
QTY
TargetMol | Inhibitor Sale
mtor/hdac-in-1
T633992815286-02-1In house
mTOR HDAC-IN-1 (Compound 50) is a dual inhibitor of mTOR and HDAC, with IC50 values of 0.49 nM and 0.91 nM, respectively, holding potential as an anti-cancer agent [1].
  • Inquiry Price
3-6 months
Size
QTY
ROCK/HDAC-IN-1
T201708
ROCK HDAC-IN-1 (Compound 10h) serves as an orally effective inhibitor of ROCK HDAC. This compound suppresses ROCK1 2 (IC50: 254.9 nM, 58.18 nM) and HDAC1 2 3 6 8 (IC50: 9.09, 8.03, 6.26, 0.41, 7.69 nM). It stimulates the activation of DAMPs, notably calreticulin (CRT) exposure and HMGB1 release, suggesting its potential as an inducer of immunogenic cell death (ICD). ROCK HDAC-IN-1 exhibits antiproliferative effects against breast cancer cells (IC50: 0.37 μM for MDA-MB-231 cells), inhibits tumor growth, activates T cells, and shows no significant toxicity.
  • Inquiry Price
10-14 weeks
Size
QTY
Givinostat
T36629497833-27-9
Givinostat (ITF-2357) is an HDAC inhibitor with IC50 values of 198 nM for HDAC1 and 157 nM for HDAC3.
    7-10 days
    Inquiry
    nr-160
    T370682484895-50-1
    NR-160 is an inhibitor of histone deacetylase 6 (HDAC6; IC50= 0.03 μM).1It is selective for HDAC6 over HDAC1, -2, -3, -4, and -8 (IC50s = 5.18, 2.26, 8.48, 55.4, and 14.7 μM, respectively). NR-160 is cytotoxic against a panel of seven cancer cell lines (IC50s = 22.5-51.8 μM). It enhances cytotoxicity induced by bortezomib in HL-60 cells, as well as cytotoxicity induced by epirubicin or daunorubicin in CCRF-HSB-2 T cell acute lymphoblastic leukemia cells.
    • Inquiry Price
    6-8 weeks
    Size
    QTY
    CAY17c
    T383812414373-11-6
    CAY17c is an inhibitor of bromodomain-containing protein 4 (BRD4; IC50= 0.71 μM), as well as class I histone deacetylases (HDACs; IC50s = 0.046, 0.058, 0.075, and 0.167 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 0.073 and 0.923 μM for HDAC6 and HDAC10, respectively).1It is selective for these enzymes over BRD2, -3, and -T (IC50s = >20 μM for all), as well as over HDAC4, -5, -7, -9, and -11 (IC50s = >10 μM for all). CAY17c inhibits the proliferation of HCT116, SW620, and DLD-1 colorectal cancer cells (IC50s = 0.45, 1.78, and 2.11 μM, respectively), as well as induces apoptosis and autophagy in HCT116 cells. It reduces tumor growth in an HCT116 mouse xenograft model when administered at doses of 15 and 30 mg/kg. 1.Pan, Z., Li, X., Wang, Y., et al.Discovery of thieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as bromodomain-containing protein 4/histone deacetylase dual inhibitors induce autophagic cell death in colorectal carcinoma cellsJ. Med. Chem.63(7)3678-3700(2020)
    • Inquiry Price
    6-8 weeks
    Size
    QTY
    hdac-in-47
    T62072
    HDAC-IN-47 is an orally active histone deacetylase (HDAC) inhibitor, with IC50 values of 19.75 nM, 57.8 nM, 40.27 nM, 5.63 nM, and 302.73 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, respectively. HDAC-IN-47 can block the cell cycle in the G2 M phase, inhibit autophagy, induce apoptosis via the Bax Bcl-2 and caspase-3 pathways, and exhibits anti-cancer activity in vivo.
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    hdac-in-38
    T629202408123-36-2
    HDAC-IN-38 is a potent inhibitor of HDAC. HDAC-IN-38 has similar micromolar inhibitory effects on HDAC1, 2, 3, 5, 6 and 8, and also increases histone acetylation levels (H3K14 or H4K5). HDAC-IN-38 increases cerebral blood flow (CBF), reduces cognitive impairment and improves hippocampal atrophy.
    • Inquiry Price
    8-10 weeks
    Size
    QTY
    Quisinostat dihydrochloride
    Quisinostat 2HCl, Quisinostat (JNJ-26481585) 2HCl, JNJ26854165(Quisinostat) 2HCl, JNJ-26481585 2HCl
    T6865875320-31-3
    Quisinostat dihydrochloride (JNJ26854165(Quisinostat) 2HCl) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.
    • Inquiry Price
    Size
    QTY
    HDAC/CD13-IN-1
    T79683
    HDAC CD13-IN-1 (Compound 12) is an inhibitor of both HDAC and CD13, with IC50 values of 0.34 μM for hCD13, 0.53 μM for porcine CD13, and 0.03, 0.06, and 0.02 μM for HDAC1, HDAC2, and HDAC3, respectively. This compound effectively suppresses proliferation and induces apoptosis in MV4-11, K562, Jeko-1, and HL60 cancer cells, with IC50 ranges of 0.25-2.04 μM, and demonstrates capabilities in hindering metastasis and invasion [1].
    • Inquiry Price
    Size
    QTY